The concentration of IL-17 and Th17 cells is significantly increased in the peripheral blood and CSF of MS patients, especially during relapses, but also in remissions, compared to healthy subjects [85, 94–96] and correlates with clinical and paraclinical disease activity [85, 97]. Here, IL17A is linked to myeloid sarcoma.